Anti-Phospho-BRCA1 (S988) Rabbit Polyclonal Antibody for IHC-P, IF/ICC, ELISA - P38398

Core Product Specifications and Parameters

Biological Background: BRCA1 Function and Localization

• Breast cancer type 1 susceptibility protein (BRCA1), also known as RING finger protein 53 (RNF53), is an E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains, playing a central role in cellular responses to DNA damage. Related references: PMID:10500182 PMID:12887909 PMID:12890688
• The BRCA1-BARD1 heterodimer coordinates diverse pathways including DNA repair, ubiquitination, and transcriptional regulation to maintain genomic stability. Related references: PMID:12890688 PMID:14976165 PMID:20351172
• BRCA1 is required for appropriate cell cycle arrests after ionizing irradiation in both S-phase and G2 phase, and contributes to homologous recombination repair (HRR) via interaction with PALB2 and fine-tuning of BRCA2-RAD51 loading at DNA breaks. Related references: PMID:10724175 PMID:11836499 PMID:12183412 PMID:19369211
• It regulates centrosomal microtubule nucleation and inhibits lipid synthesis by binding to inactive phosphorylated ACACA, preventing its dephosphorylation. Related references: PMID:18056443 PMID:16326698
• The BRCA1-RBBP8 complex controls G2/M checkpoint activation via ubiquitination of RBBP8, illustrating a direct regulatory mechanism in cell cycle progression after DNA damage. Related references: PMID:16818604
• Subcellular localization includes nucleus, chromosome, and cytoplasm, with dynamic shuttling depending on cell cycle stage and DNA damage signals.
• Post‑translational modifications include phosphorylation (e.g., at S988), acetylation, and ubiquitination, which modulate its activity and interactions.
• Isoform 1 and 3 are widely expressed; isoform 3 is often reduced or absent in breast and ovarian cancer cell lines.

Experimental Guidance and Technical Tips

• The immunogen is a synthetic phosphopeptide around S988 of human BRCA1; antibody specificity for the phosphorylated form should be confirmed by phosphatase treatment or competition assays.
• For IHC-P, optimize antigen retrieval and consider using tissues with known BRCA1 expression (e.g., breast, ovary); include a negative control using a non‑phospho‑blocking peptide.
• In IF/ICC, co‑staining with DNA damage markers or cell cycle phase markers can provide functional context for BRCA1 localization.
• ELISA detection of phospho‑BRCA1 may require careful extraction and normalization to total BRCA1 levels; validate linearity and sensitivity in the relevant sample matrix.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio offers diagnostic manufacturers, research laboratories, and clinical assay developers streamlined access to validated IVD raw materials. We support your BRCA1‑related cancer and DNA damage pathway projects with optimized monoclonal and polyclonal antibodies, recombinant proteins, and ancillary reagents. As a dedicated B2B partner, CamelBio bridges the gap from concept to clinic with reliable supply of high‑quality immunoreagents and rare‑target sourcing capabilities.